It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Please provide your email address to receive an email when new articles are posted on . At any given PSA level, Black men are more likely than white men to harbor prostate cancer, according to ...

A Prostate-Specific Antigen (PSA) test is a procedure formed on men to detect prostate cancer. It is considered an effective means of cancer screening and can be used to monitor the effectiveness of ...

Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less.To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...